News
MODULATING DNA DAMAGE RESPONSES TO CURE CANCER
Contact Us
Breakpoint Therapeutics GmbH
Essener Bogen 7
22419 Hamburg (Germany)
Telefon: +49 40 56081 180
E-mail: info@breakpointtx.com
Impressum
Registergericht: Hamburg
Registernummer: HRB 155717
Umsatzsteuer-Identifikationsnummer: DE 324 797 830
Geschäftsführer / Managing Directors
Dr. Daniel Speidel and Jonathan Hollick
Breakpoint To Present At BIO Investor Forum
Breakpoint’s Managing Director Daniel Speidel will present a company overview at BIO Investor Forum in San Francisco on October 18, 2023. 10:00am, Franciscan C.
Breakpoint To Present At BIO International Convention 2023
Breakpoint’s Managing Director Daniel Speidel will present a company overview at BIO International Convention in Boston on June 7, 2023. 12:15pm, Session Room 104A.
Breakpoint To Present At DDR Inhibitors Summit, 2023
Breakpoint’s Managing Director and Head of Research Jon Hollick will give a talk entitled “Next Generation DDR/Synthetic Lethality Targets: Mining DNA Metabolism for Gold” at the DDR Inhibitors Summit in Boston, 24-26 January 2023.